Related references
Note: Only part of the references are listed.Pharmacokinetics and tolerability of semaglutide in people with hepatic impairment
Lene Jensen et al.
DIABETES OBESITY & METABOLISM (2018)
Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species
Lene Jensen et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2017)
Novel strategies in the oral delivery of antidiabetic peptide drugs - Insulin, GLP 1 and its analogs
Ruba Ismail et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2017)
Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes A Randomized Clinical Trial
Melanie Davies et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Achievement of Glycated Hemoglobin Goals in the US Remains Unchanged Through 2014
Ginger Carls et al.
DIABETES THERAPY (2017)
Achievement of Glycated Hemoglobin Goals in the US Remains Unchanged Through 2014
Ginger Carls et al.
DIABETES THERAPY (2017)
Pharmacokinetics and Tolerability of a Single Dose of Semaglutide, a Human Glucagon-Like Peptide-1 Analog, in Subjects With and Without Renal Impairment
Thomas C. Marbury et al.
CLINICAL PHARMACOKINETICS (2017)
Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity
John Blundell et al.
DIABETES OBESITY & METABOLISM (2017)
8. Pharmacologic Approaches to Glycemic Treatment
DIABETES CARE (2016)
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
Matthew James Armstrong et al.
LANCET (2016)
Semaglutide, a Once-Weekly Human GLP-1 Analog, Does Not Reduce the Bioavailability of the Combined Oral Contraceptive, Ethinylestradiol/Levonorgestrel
Christoph Kapitza et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide
Jesper Lau et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
Silvio E. Inzucchi et al.
DIABETES CARE (2015)
Pharmacokinetics in Patients with Chronic Liver Disease and Hepatic Safety of Incretin-Based Therapies for the Management of Type 2 Diabetes Mellitus
Andre J. Scheen
CLINICAL PHARMACOKINETICS (2014)
Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society
Elizabeth R. Seaquist et al.
DIABETES CARE (2013)
Influence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue, liraglutide
Anne Flint et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Novel therapeutics for type 2 diabetes: Incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors
E. J. Verspohl
PHARMACOLOGY & THERAPEUTICS (2009)
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
Daniel J. Drucker et al.
LANCET (2006)
Share Paper
